04 November 2022 The topic was re-considered by the Topic Selection Oversight Panel (TSOP) in September 2022. The panel concluded that the topic should remain routed to the Technology Appraisal (TA) ...

Alagille Syndrome (ALGS) is a genetic disorder that primarily affects the liver but can also impact various other organ systems, including the heart, kidneys, and eyes. It is characterized by ...

its treatment for severe itching (pruritus) in patients with the rare liver disease Alagille syndrome (ALGS). Kayfanda (odevixibat) is labelled in the EU to treat cholestatic pruritus – itching ...

Hello, and welcome to Mirum Pharmaceuticals reports fourth quarter and year-end 2024 financial results and provides business update. My name is Elliot, and I'll be your coordinator today. (Operator ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older.

To answer this, researchers from Karolinska Institutet and Charles University studied a genetic disease called Alagille ...

In 2021, Livmarli was approved by the FDA to treat cholestatic pruritus in patients with Alagille syndrome (ALGS), a genetically driven multisystem disorder. Japanese pharma giant Takeda (TAK ...

Courtney said not a day goes by where Alex doesn’t tear himself from itching. Doctors have told Courtney it is the worst case of alagille syndrome they have ever seen for a child of Alex’s age.

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

that is currently approved to treat itching associated with two other rare liver diseases, Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). Ipsen is currently not ...